Thursday, October 30, 2025

Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin

Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted a fifth patent in the United States. The patent is related to what is referred to as crystalline psilocybin.

More specifically, the patent covers methods of treating treatment-resistant depression through the use of crystalline psilocybin. The patent also covers the use of oral dosage forms of the psilocybin with an excipient, which in layman terms means the psilocybin can be used in oral dosage format with a bulking agent, which can boost stability or bioavailability.

Notably, the tech protected by this latest patent is being utilized in COMP360, the firms formulation of synthesized psilocybin it is currently investigating for treatment against treatment-resistant depression.

The patent is the fifth for the company in the US, and its tenth globally. The firm currently holds two patents in each of Hong Kong and the United Kingdom, and one in Germany. As per the company, the patents “enable [Compass] to continue to do the highest quality clinical research.”

Compass Pathways last traded at $30.23 on the Nasdaq.


Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Compass Pathways President Steps Down To An Advisory Role

Compass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of...

Thursday, December 16, 2021, 11:18:00 AM

Compass Pathways Sees “Reduction In Depressive Symptom” In Phase IIb Psilocybin Clinical Trial

Compass Pathways (Nasdaq: CMPS) announced today that its phase IIb clinical trial of COMP360 psilocybin therapy...

Tuesday, November 9, 2021, 12:33:00 PM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Compass Pathways, Psilocybin Research Firm, Files For Nasdaq IPO

It appears that some authenticity and validation might be coming to the psychedelics space. Compass...

Saturday, August 29, 2020, 11:43:00 AM

Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial

Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the...

Monday, June 28, 2021, 07:37:00 AM